Company Overview of Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company’s clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kin...
1180 Veterans Boulevard
South San Francisco, CA 94080
Founded in 1996
Key Executives for Rigel Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $618.0K
Chief Financial Officer and Executive Vice President
Total Annual Compensation: $454.6K
Executive Vice President of Corporate Affairs, General Counsel and Corporate Secretary
Total Annual Compensation: $489.8K
Chief Medical Officer and Executive Vice President
Total Annual Compensation: $358.2K
Chief Commercial Officer and Executive Vice President
Total Annual Compensation: $86.6K
Compensation as of Fiscal Year 2016.
Rigel Pharmaceuticals, Inc. Key Developments
Rigel Pharmaceuticals, Inc Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
Apr 17 17
Rigel Pharmaceuticals, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for fostamatinib in patients with chronic and persistent immune thrombocytopenia (ITP). The NDA is supported by data from the Phase 3 clinical program for fostamatinib in ITP, which was comprised of three studies, two randomized placebo-controlled studies (Studies 047 and 048) and an open-label extension study (Study 049). In total, 163 ITP patients have been evaluated and included in the NDA submission. Across all indications, fostamatinib has been evaluated in over 4,600 subjects. Data from all studies, including preclinical evaluation and drug manufacturing data, were included in the NDA submission. The company expects to receive notification regarding the acceptance of the NDA by the FDA in June 2017. The FDA previously granted Orphan Drug designation to fostamatinib for the treatment of patients with ITP.
Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2016
Mar 7 17
Rigel Pharmaceuticals, Inc. reported unaudited earnings results for the fourth quarter and year ended December 31, 2016. For the fourth quarter of 2016, Rigel reported a net loss of $15.6 million, or $0.16 per basic and diluted share, compared to a net loss of $12.7 million, or $0.14 per basic and diluted share, in the fourth quarter of 2015. Contract revenues from collaborations of $3.0 million in the fourth quarter of 2016 against $8.5 million reported in the fourth quarter of 2015. Loss from operations was $15.8 million against $12.7 million reported last year.
For the year ended December 31, 2016, Rigel reported contract revenues from collaborations of $20.4 million and a net loss of $69.2 million, or $0.73 per basic and diluted share, compared to contract revenues from collaborations of $28.9 million and a net loss of $51.5 million, or $0.58 per basic and diluted share, in 2015. Contract revenues from collaborations in 2016 were mainly comprised of the $13.4 million amortization of the upfront payment, $3.0 million contingent payment received and $290,000 in FTE fees earned from BMS, as well as the $3.7 million contingent payment received from BerGenBio AS. Loss from operations was $69.7 million against $51.7 million reported last year.
Rigel Pharmaceuticals, Inc. to Report Q4, 2016 Results on Mar 07, 2017
Mar 2 17
Rigel Pharmaceuticals, Inc. announced that they will report Q4, 2016 results After-Market on Mar 07, 2017
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|